It may be possible to improve predictive power of repolarization biomarkers if ECG sampling is expanded beyond beats with low and stable heart rates

Read the full Clinical and Transitional Science (CTS) publication here

St. Paul, MN – Since introduction of the International Conference on Harmonization proarrhythmia guidelines in 2005, no new marketed drugs have been associated with unacceptable risk of Torsade de Pointes. Although cardiac safety improved, these guidelines had the unintended consequence of eliminating potentially beneficial drugs from pipelines early in development. More recently, it has been shown that a corrected QT (QTc) prolonging drug may be safe if it impacts multiple ion channels vs. only human ether‐a‐go‐go related gene (hERG) and that this effect can be discriminated using QT subintervals.

We compared the predictive power of four electrocardiogram (ECG) repolarization metrics to discriminate single vs. multichannel block: (i) traditional 10‐second signal averaged triplicates, and (ii) three metrics that used increasing density of automatically measured beat‐to‐beat (btb) intervals.

Predictive power was evaluated using logistic regression and quantified with receiver operating characteristic (ROC) area under the curve (AUC). Compared with the traditional 10‐second signal averaged triplicates, the reduction in classification error ranged from 2−6 with increasing density of btb measurements.

About VivaQuant

VivaQuant provides ECG analysis services to evaluate the safety and efficacy of drugs and devices. Its patented Multi-Domain Signal Processing (MDSPTM) technology removes up to 95 percent of noise and artifact in ambulatory ECGs, resulting in improved measurement accuracy and less labor.

For additional information email us at [email protected].